Japan OKs Actelion's Tracleer for PAH
Swiss drugmaker Actelion says that the Japanese Ministry of Health, Labor and Welfare has granted formal approval for its oral dual endothelin receptor antagonist Tracleer (bosentan) for the treatment of all forms of pulmonary arterial hypertension.
The group is in discussions with reimbursement authorities to finalize pricing, and expects to introduce the drug, which has a peak sales forecast of $400.0-$500.0 million for the PAH indication alone, in Japan by early June 2005.
Satoshi Tanaka, president of Actelion Japan, noted: "since its first market introduction in late-2001, Tracleer has revolutionized the treatment of PAH, a serious and life-threatening disease."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze